

# Medlab Clinical Ltd

16:07 02 Oct 2019

## Medlab Clinical begins NanoCBD manufacturing after first export order for NanoCelle platform-based cannabinoid product

Medlab Clinical Ltd (ASX:MDC) has begun manufacturing its NanoCBD product at a licensed FDA facility after receiving its first export order to Hong Kong for 1,500 units of the cannabinoid product.

Australian delivery for use under the Special Access Scheme is expected by Christmas 2019.

This is the third cannabinoid product Medlab has produced and like the previous two, it utilises Medlab's proprietary delivery system NanoCelle and maintains all the rigours of quality in the manufacturing cycle.

Other countries that allow CBD from hemp instead of marijuana, specifically the US market, are being investigated with potential partners.

"Capabilities of NanoCelle delivery platform"

Medlab chief executive officer Sean Hall said: "NanoCBD is another example of the capabilities of Medlab's patented NanoCelle delivery platform

"The order is the start of global expansion for the product, with opportunities in the USA to follow.

"Once manufactured, NanoCBD will be available in Australia under SAS."

Local and global commercial opportunities

NanoCBD is a standardised formulation containing 16.67 milligrams per millilitre cannabidiol from hemo, as an active ingredient, in a sub-micron spray applied to the oro-bucal membrane.

NanoCBD has local and global commercial opportunities, allowing for expanded commercial reach where hemp products have been legalised.

Like Medlab's other two cannabis products NanaBis and NanaBidial, NanoCBD is made under either an Australian (TGA) or US (FDA) approved drug manufacturer to ensure quality and consistency in the formulation.

Three business divisions

Pharmaceuticals is one of three Medlab divisions, along with the Nutraceuticals business and the Medlab technologies group focused on commercialising NanoCelle.

Medlab's core objective for the Pharmaceutical division is to achieve a drug registration with approved health claims, for example, NanaBis where it

**Price:** 0.325

**Market Cap:** \$69.99 m

### 1 Year Share Price Graph



### Share Information

**Code:** MDC

**Listing:** ASX

52 week	High	Low
	0.56	0.3

**Sector:** Cannabis

**Website:** [www.medlab.co](http://www.medlab.co)

### Company Synopsis:

Medlab Clinical Ltd (ASX:MDC) is listed on the Australian Securities Exchange.

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

continues to make progress through the phase-two clinical trial at Royal North Shore.

Trial progress and the pursuit of drug registration will underwrite a global opportunity in pain management.

#### Patient data and revenue

In conjunction with the drug registration process, Medlab continues to exercise numerous other paths of commercialisation including product sales in compassionate access schemes such as the Australian TGA SAS category B scheme and other over-the-counter opportunities globally.

These initiatives provide valuable patient data and revenue.

#### Clinical claims

The Pharmaceutical approach uniquely differentiates Medlab from others in the cannabis sector, which are not exposed to the rigours of clinical trials, manufacturing at licenced drug facilities, or oversight and scrutiny from the TGA, FDA and the EMA.

Medlab's portfolio of potential clinical claims now include:

NanaBis - cancer pain, but also showing very encouraging data in neuropathic pain;

NanaBidial - seizures and chemotherapy-induced nausea and vomiting; and

NanoCBD - inflammation, anxiety.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

#### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price

and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).